High-Risk Obesity Phenotypes : Target for Multimorbidity Prevention at the ROFEMI Study
Background: Describe the profile of patients with obesity in internal medicine to determine the role of adiposity and related inflammation on the metabolic risk profile and, identify various “high-risk obesity” phenotypes by means of a cluster analysis. This study aimed to identify different profiles of patients with high-risk obesity based on a cluster analysis. Methods: Cross-sectional, multicenter project that included outpatients attended to in internal medicine. A total of 536 patients were studied. The mean age was 62 years, 51% were women. Patients were recruited from internal medicine departments over two weeks in November and December 2021 and classified into four risk groups according to body mass index (BMI) and waist circumference (WC). High-risk obesity was defined as BMI > 35 Kg/m2 or BMI 30−34.9 Kg/m2 and a high WC (>102 cm for men and >88 cm for women). Hierarchical and partitioning clustering approaches were performed to identify profiles. Results: A total of 462 (86%) subjects were classified into the high-risk obesity group. After excluding 19 patients missing critical data, two profiles emerged: cluster 1 (n = 396) and cluster 2 (n = 47). Compared to cluster 1, cluster 2 had a worse profile, characterized by older age (77 ± 16 vs. 61 ± 21 years, p < 0.01), a Charlson Comorbidity Index > 3 (53% vs. 5%, p < 0.001), depression (36% vs. 19%, p = 0.008), severe disability (64% vs. 3%, p < 0.001), and a sarcopenia score ≥ 4 (79% vs. 16%, p < 0.01). In addition, cluster 2 had greater inflammation than cluster 1 (hsCRP: 5.8 ± 4.1 vs. 2.1 ± 4.5 mg/dL, p = 0.008). Conclusions: Two profiles of subjects with high-risk obesity were identified. Based on that, older subjects with obesity require measures that target sarcopenia, disability, psychological health, and significant comorbidities to prevent further health deterioration. Longitudinal studies should be performed to identify potential risk factors of subjects who progress from cluster 1 to cluster 2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 16 vom: 09. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carretero-Gómez, Juana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adiposity |
|---|
| Anmerkungen: |
Date Revised 08.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11164644 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34531283X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34531283X | ||
| 003 | DE-627 | ||
| 005 | 20231226024759.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11164644 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM34531283X | ||
| 035 | |a (NLM)36012889 | ||
| 035 | |a (PII)4644 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carretero-Gómez, Juana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-Risk Obesity Phenotypes |b Target for Multimorbidity Prevention at the ROFEMI Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Describe the profile of patients with obesity in internal medicine to determine the role of adiposity and related inflammation on the metabolic risk profile and, identify various “high-risk obesity” phenotypes by means of a cluster analysis. This study aimed to identify different profiles of patients with high-risk obesity based on a cluster analysis. Methods: Cross-sectional, multicenter project that included outpatients attended to in internal medicine. A total of 536 patients were studied. The mean age was 62 years, 51% were women. Patients were recruited from internal medicine departments over two weeks in November and December 2021 and classified into four risk groups according to body mass index (BMI) and waist circumference (WC). High-risk obesity was defined as BMI > 35 Kg/m2 or BMI 30−34.9 Kg/m2 and a high WC (>102 cm for men and >88 cm for women). Hierarchical and partitioning clustering approaches were performed to identify profiles. Results: A total of 462 (86%) subjects were classified into the high-risk obesity group. After excluding 19 patients missing critical data, two profiles emerged: cluster 1 (n = 396) and cluster 2 (n = 47). Compared to cluster 1, cluster 2 had a worse profile, characterized by older age (77 ± 16 vs. 61 ± 21 years, p < 0.01), a Charlson Comorbidity Index > 3 (53% vs. 5%, p < 0.001), depression (36% vs. 19%, p = 0.008), severe disability (64% vs. 3%, p < 0.001), and a sarcopenia score ≥ 4 (79% vs. 16%, p < 0.01). In addition, cluster 2 had greater inflammation than cluster 1 (hsCRP: 5.8 ± 4.1 vs. 2.1 ± 4.5 mg/dL, p = 0.008). Conclusions: Two profiles of subjects with high-risk obesity were identified. Based on that, older subjects with obesity require measures that target sarcopenia, disability, psychological health, and significant comorbidities to prevent further health deterioration. Longitudinal studies should be performed to identify potential risk factors of subjects who progress from cluster 1 to cluster 2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adiposity | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a phenotypes | |
| 650 | 4 | |a waist circumference | |
| 700 | 1 | |a Pérez-Martínez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Seguí-Ripoll, José Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco-Sánchez, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Lois Martínez, Nagore |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Pérez, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Hernández, Onán |e verfasserin |4 aut | |
| 700 | 1 | |a García Ordoñez, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Martín González, Candelaria |e verfasserin |4 aut | |
| 700 | 1 | |a Vigueras-Pérez, Juan Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Puchades, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Blasco Avaria, María Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Soto, María Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Ena, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Arévalo-Lorido, José Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of Diabetes Obesity And Nutrition Working Group Of Spanish Society Of Internal Medicine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 16 vom: 09. Aug. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:16 |g day:09 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11164644 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 16 |b 09 |c 08 | ||